KemPharm Participating in BIO @ JPM and Fierce JPM Week 2021 Virtual Events During “J.P. Morgan Week 2021”
KemPharm (NASDAQ: KMPH), a specialty pharmaceutical company, announced participation in BIO @ JPM and Fierce JPM Week 2021, held virtually in January. The management team will engage in one-on-one meetings to discuss recent achievements and potential milestones, highlighting KP415, an investigational product for ADHD, with a PDUFA date set for March 2, 2021. KP415 aims to enhance ADHD treatment by improving action onset and duration while minimizing adverse effects associated with traditional medications.
- Participation in major industry events to enhance visibility and networking.
- Focus on KP415 with a PDUFA date of March 2, 2021, indicating progress in drug approval.
- No detailed financial data or results provided, leaving uncertainties about current performance.
CELEBRATION, Fla., Jan. 13, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that the company is participating in BIO @ JPM and Fierce JPM Week 2021. Both events are being held virtually during the month of January alongside the J.P. Morgan 39th Annual Healthcare Conference 2021.
Details of the events are as follows:
| Event: | BIO @ JPM | |
| Date: | January 11-15, 2021 | |
| Registration: | https://www.bio.org/events/bio-partnering-jpm/registration | |
| Event: | Fierce JPM Week 2021 | |
| Date: | January 11-13, 2021 | |
| Registration: | https://2021outlook.fiercelifesciences.com/Register |
During both events, members of the KemPharm management team are participating in virtual one-on-one meetings with registered attendees to discuss KemPharm’s business and highlight recent corporate achievements, as well as potential milestones, including the anticipated March 2, 2021 PDUFA date for KP415. KP415 is KemPharm’s investigational product candidate for the treatment of ADHD. KP415 consists of serdexmethylphenidate (SDX), KemPharm’s prodrug of d-methylphenidate (d-MPH), co-formulated with immediate-release d-MPH. KP415 is designed to address unmet needs with the most widely-prescribed methylphenidate ADHD treatments, including earlier onset of action and longer duration of therapy, while avoiding unnecessary spikes in d-MPH concentrations that may be associated with adverse events.
About KemPharm:
KemPharm is a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its proprietary LAT® (Ligand Activated Therapy) technology. KemPharm utilizes its proprietary LAT® technology to generate improved prodrug versions of FDA-approved drugs as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. KemPharm’s prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, or ADHD, and stimulant use disorder. KemPharm’s co-lead clinical development candidates for the treatment of ADHD, KP415 and KP484, are both based on a prodrug of d-methylphenidate, but have differing duration/effect profiles. In addition, KemPharm has received FDA approval for APADAZ®, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. For more information on KemPharm and its pipeline of prodrug product candidates visit www.kempharm.com or connect with us on Twitter, LinkedIn, Facebook and YouTube.
Caution Concerning Forward Looking Statements:
This press release may contain forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company’s proposed development and commercial timelines, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements, including the timing of the PDUFA date and potential FDA approval of the KP415 NDA, or the potential clinical benefits of KP415 are based on information currently available to KemPharm and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning KemPharm’s business are described in detail in KemPharm’s Annual Report on Form 10-K for the year ended December 31, 2019, KemPharm’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, and KemPharm’s other Periodic and Current Reports filed with the Securities and Exchange Commission. KemPharm is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
| KemPharm Contacts: |
| Jason Rando / Maureen McEnroe Tiberend Strategic Advisors, Inc. 212-375-2665 / 2664 jrando@tiberend.com mmcenroe@tiberend.com |
FAQ
What is the significance of KemPharm's participation in BIO @ JPM 2021?
When is the PDUFA date for KP415?
What is KP415 developed by KemPharm?
What events is KemPharm participating in January 2021?
